A Phase 2, Randomized, Placebo-controlled Multi-center Study to Investigate the Efficacy and Safety, of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Celgene Corporation
- 31 Oct 2017 Planned End Date changed from 29 Aug 2019 to 31 May 2019.
- 27 Jul 2017 According to a Celgene Corporation media release, top-line results from this trial are expected by year-end 2017.
- 21 Jul 2017 Status changed from recruiting to active, no longer recruiting.